

Foralumab Study



Are you or a loved one suffering from memory loss or struggling to complete daily tasks? You may be eligible to participate in a clinical trial for early Alzheimer's disease.

- This study will enroll 16 participants at Brigham and Women's Hospital
- This study will be testing a drug called Foralumab with the goal of improving cognitive function
- There will be a few initial screening visits to ensure you are eligible for the study

There is no cost associated with participating in this study

Estimated Time Commitment: This study will last about 5 months and may include up to 8 visits.

You May Be Eligible If: You are between 60-85 years old, are of any gender, and have a diagnosis of mild cognitive impairment due to Alzheimer's disease or dementia.

May Be Offered: Financial compensation for each visits and parking reimbursement / coverage

May Be Required: Clinic visits that may include: thinking and memory testing, physical and neurological exams, ECG scans, blood draws, urine testing, nasal medication spray, brain imaging (MRI and PET scans)

If you are interested and would like more information, please contact CART:

Phone: 617-732-8085

Email: CART@mgb.org

What we are studying:

This study will look at whether the investigational drug (Foralumab) can slow or improve cognitive decline in patients with early symptomatic Alzheimer's disease or dementia.

Why is this study important?

Currently, there is no cure for Alzheimer's Disease. This clinical trial will test if the investigational drug can improve the function of microglial cells in the brain, which is known to play a role in clearing amyloid plaques. Changes in levels of these amyloid plaques may be crucial to improving thinking and memory function in those with dementia or AD.

Who can participate?

You may be eligible for this study if you are:

- Ages 60 to 85 years old.
- Have a diagnosis of Alzheimer's disease or dementia
- Have a study partner who knows you and is willing to attend visits with you throughout the study.

About the investigational medication:

In this study, you will either receive the drug Foralumab or placebo. Participants will be randomly assigned to receive nasal spray doses of either Foralumab or placebo. A placebo looks like a drug but has no active ingredient. The drug will be administered by you (or your caregiver) daily for a period of time into each nostril with a device that is similar to Flonase or any generic nasal spray for allergies.

What you may get:

- On-site parking at no cost to you.
- Reimbursement for each visit.

Location:

Center for Alzheimer Research and Treatment (CART)
Brigham and Women's Hospital
60 Fenwood Road
Boston, MA 02115